Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
NCT00823290
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class
Stopped
Investigator left site
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Sorafenib + LBH589
Sponsor
University of Erlangen-Nürnberg Medical School